Biophytis SA American Depositary Share (BPTS)

Etorro trading 970x250

About Biophytis SA American Depositary Share

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company’s lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France. Address: Sorbonne University, Paris, France, 75005

Biophytis SA American Depositary Share News and around…

Latest news about Biophytis SA American Depositary Share (BPTS) common stock and company :

12 Health Care Stocks Moving In Friday's Intraday Session
22 Oct, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
20 Oct, 2021 FinancialContent

Gainers Sesen Bio (NASDAQ:SESN) stock increased by 29.2% to $1.3 during Wednesday's regular session. Trading volume ...

12 Health Care Stocks Moving In Thursday's Intraday Session
07 Oct, 2021 FinancialContent

Gainers Nanobiotix (NASDAQ:NBTX) shares rose 13.2% to $12.0 during Thursday's regular session. The market value of ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Biophytis to Restate Previously Issued Financial Statements
06 Oct, 2021 Yahoo! Finance

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announced that the Company’s previously iss

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia
06 Oct, 2021 Yahoo! Finance

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will host a virtual key opinion leader (KOL) event on October

Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million
04 Oct, 2021 Yahoo! Finance

PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the issuance of 240 Bonds Redeemable in Cash and New and Exist

Biophytis Announces Promising Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
04 Oct, 2021 Yahoo! Finance

Figure 1 Effect of Sarconeos (BIO101) on the 400 MWT gait speed in the FAS and PP populations Figure 2 Effect of Sarconeos (BIO101) on the 400MWT gait speed in sub-population with higher risk of mobility disability (chair stand subscore ≤2) Figure 3 Adverse Events, Serious Adverse Events and Treatment Emergent Adverse Events in the Placebo, 175 mg bid and 350 mg bid groups in the SARA-INT study Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the

12 Health Care Stocks Moving In Thursday's Pre-Market Session
30 Sep, 2021 FinancialContent

Gainers OptimizeRx (NASDAQ:OPRX) stock increased by 12.12% to $84.05 during Thursday's pre-market session. The ...

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

18 Stocks Moving in Thursday's Pre-Market Session
30 Sep, 2021 FinancialContent

Gainers Superior Drilling Products, Inc. (NYSE: SDPI) rose 58.7% to $1.73 in pre-market trading after jumping over 23% on ...

Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September
29 Sep, 2021 FinancialContent
Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
29 Sep, 2021 Yahoo! Finance

PARIS and CAMBRIDGE, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will present full results from the SARA-INT Phase 2 trial of

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Biophytis Reports H1 2021 Financial Results and Provides Business Update
17 Sep, 2021 FinancialContent
Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19
15 Sep, 2021 FinancialContent
Biophytis to Attend Key Upcoming Investor Events and Industry Conferences
14 Sep, 2021 FinancialContent
Biophytis Leadership is Reinforced With New Chief Medical Officer Appointment
09 Sep, 2021 FinancialContent
DMC Recommends Biophytis Continue Sarconeos COVID-19 Study
16 Aug, 2021 FinancialContent

The Data Monitoring Committee (DMC) has recommendedBiophytis SA(NASDAQ: BPTS)to continue patient ...

Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the COVA Study in COVID-19
16 Aug, 2021 FinancialContent
Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of the Judgments of March 16, 2021 and July 16, 2021
13 Aug, 2021 FinancialContent
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
10 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Monday
09 Aug, 2021 FinancialContent

Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market ...

Stocks That Hit 52-Week Lows On Wednesday
04 Aug, 2021 FinancialContent

Wednesday's morning session saw 58 companies set new 52-week lows. Noteworthy Mentions: The company ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
02 Aug, 2021 FinancialContent

Gainers Exicure (NASDAQ:XCUR) stock moved upwards by 35.55% to $1.83 during Monday's pre-market session. The ...

Biophytis Stock Gains As Sarconeos High Dose Improves Gait Speed Versus Placebo In Patients With Muscle Loss Due To Aging
02 Aug, 2021 FinancialContent

Biophytis SA(NASDAQ: BPTS)has announced top-line resultsof the SARA-INT phase 2 clinical study with Sarconeos ...

Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia
02 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Biophytis SA American Depositary Share (BPTS) is a NASDAQ Common Stock listed in , ,

970x250